Viewing nowShinil Glimepiride Tablets (Gliclazide)
Gliclazide 80mg
Tablet · Prescription medication
(Shinil Pharmaceutical Co., Ltd.)

MFDS item code 199202050 · Notified 1992.01.04
Treatment of type 2 diabetes mellitus inadequately controlled by diet and exercise
This medication is used for patients with type 2 diabetes who have difficulty controlling blood sugar levels with diet and exercise alone. It helps effectively manage blood glucose levels and prevent complications.
(Tablets)(Capsules) Adults: Start with 40~80mg per day of gliclazide, administered orally in 1~2 divided doses. Thereafter, to achieve optimal control of the patient's blood glucose, the dose may be increased according to the patient's condition to a maximum of 320mg per day, administered in 2 divided doses. Do not exceed 160mg per dose. The dose must be adjusted according to the patient's condition. Additional treatment may be required in obese patients or in patients who do not respond adequately to this medication alone. (Extended-release tablets) Adults: Administer 30~120mg of gliclazide orally once daily in the morning, adjusting the dose according to blood glucose levels. If a dose is missed, do not increase the dose the following day. When this medication is taken with another blood glucose-lowering agent, the dose should be adjusted according to the individual patient's metabolic response (blood glucose, glycated hemoglobin). * Initial dose The recommended initial dose is 30mg per day. - If blood glucose control is satisfactory, maintain this dose as the maintenance dose. - If blood glucose control is unsatisfactory, the dose may be increased gradually to 60, 90, and 120mg per day at intervals of at least 1 month. If blood glucose has not decreased after 15 days of treatment, increase the dose from the end of the 2nd week of treatment. Do not exceed the maximum dose of 120mg per day. * When switching from gliclazide 80mg to gliclazide extended-release tablets 30mg, patients stabilized on gliclazide 80mg should be treated according to the principle that "gliclazide 80mg=gliclazide extended-release tablets 30mg." * When switching from another oral blood glucose-lowering agent to gliclazide extended-release tablets 30mg, the dose and half-life of the previous blood glucose-lowering agent should be taken into account. In general, switching can be done without any transitional washout period; therefore, start this medication at 30mg per day and gradually increase the dose according to each patient's metabolic response, as described in the "Initial dose" section. For patients switching from a sulfonylurea blood glucose-lowering agent with a long half-life, a washout period of several days is required to prevent the risk of hypoglycemia due to the additive effects of the two medications. * Concomitant use with other oral blood glucose-lowering agents This medication may be used in combination with biguanides, α-glucosidase inhibitors, or insulin. * Patients aged 65 years or older and patients with renal impairment This medication may be prescribed using the same administration method as for patients aged 65 years or younger with normal renal function. * Patients at risk of hypoglycemia - Poor nutritional status or malnutrition - Severe or moderate compensated endocrine disorders (anterior pituitary insufficiency, hypothyroidism, corticotropin insufficiency) - Withdrawal from long-term and/or high-dose corticosteroid therapy - Severe vascular disease (severe coronary heart disease, severe carotid artery disease, diffuse vascular disease) → Initiation at the minimum dose of 30mg per day is recommended.
This medication is a sulfonylurea that works to lower blood sugar levels. However, hypoglycemia may occur after administration, so the dosage and administration must be adhered to precisely, and immediate action must be taken if symptoms of hypoglycemia appear. It should not be administered to patients with diabetic ketoacidosis, diabetic coma, type 1 diabetes, or severe liver or kidney dysfunction. Additionally, it should not be used in patients with severe infections, trauma, pre- and post-operative patients, patients with severe gastrointestinal disorders, or patients allergic to this medication or similar drugs. Pregnant or breastfeeding women should also refrain from taking this medication, and it should not be administered to patients with specific enzyme deficiencies. Patients with slightly reduced liver or kidney functions, those with poor nutritional status or irregular eating habits, elderly patients, and excessive alcohol consumers should use this medication cautiously. Symptoms of hypoglycemia may include weakness, severe hunger, tremors, headaches, confusion, drowsiness, and seizures, so immediate intake of sugar is necessary if these symptoms appear. Adverse reactions may occur in blood, liver, digestive system, skin, etc., so consult a doctor if any unusual symptoms arise. This medication is used as an adjunct when other diabetes treatments are insufficient, and the dosage should be adjusted while regularly monitoring blood glucose and urine sugar levels. While intake of sugar is helpful in the event of hypoglycemic symptoms, artificial sweeteners are ineffective. Using this medication in combination with specific other drugs may increase the risk of hypoglycemia, so medical guidance should be followed for co-administration. During pregnancy, it should not be used as it may affect the fetus, and it is also safest not to use it while breastfeeding. Safety in pediatric patients has not been established, and caution is required as elderly individuals have a higher risk of hypoglycemia. In the case of overdose, hypoglycemic symptoms may manifest, and severe cases require immediate medical treatment. Caution should be taken for hypoglycemic symptoms when driving or operating machinery, especially in the early stages of treatment. This medication should be stored out of reach of children, and it is advisable not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air intrusion and kept at room temperature between 1 and 30 degrees Celsius. This will help maintain the effectiveness of the medication and prevent degradation.
White round tablets
30 tablets/bottle, 1000 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowGliclazide 80mg
Tablet · Prescription medication
(Shinil Pharmaceutical Co., Ltd.)

Gliclazide 80mg
Tablet · Prescription medication
(Samchundang Pharmaceuticals Co., Ltd.)

Gliclazide 80mg
Tablet · Prescription medication
(Samnam Pharmaceutical Co., Ltd.)
Gliclazide 80mg
Tablet · Prescription medication
SK Chemicals Co., Ltd.

Gliclazide 80mg
Tablet · Prescription medication
Teragen Itex Co., Ltd.

Gliclazide 30mg
Tablet · Prescription medication
Korea Servier Co., Ltd.

Gliclazide 60mg
Tablet · Prescription medication
Korea Servier Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.